These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34957213)

  • 1. Comprehensive Analysis of the Potential Immune-Related Biomarker Transporter Associated With Antigen Processing 1 That Inhibits Metastasis and Invasion of Ovarian Cancer Cells.
    Li X; Zeng S; Ding Y; Nie Y; Yang M
    Front Mol Biosci; 2021; 8():763958. PubMed ID: 34957213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy.
    Tu Z; Li K; Ji Q; Huang Y; Lv S; Li J; Wu L; Huang K; Zhu X
    BMC Cancer; 2023 Feb; 23(1):133. PubMed ID: 36759763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of TAP1 in the identification of immune-hot tumor microenvironment and its prognostic significance for immunotherapeutic efficacy in gastric carcinoma.
    He Z; Yang H; Chen Q; Chen YP; Qin H; He W; Chen Z
    J Gastrointest Oncol; 2024 Jun; 15(3):890-907. PubMed ID: 38989426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAP1, a potential immune-related prognosis biomarker with functional significance in uveal melanoma.
    Zhu R; Chen YT; Wang BW; You YY; Wang XH; Xie HT; Jiang FG; Zhang MC
    BMC Cancer; 2023 Feb; 23(1):146. PubMed ID: 36774490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer.
    Tabassum A; Samdani MN; Dhali TC; Alam R; Ahammad F; Samad A; Karpiński TM
    J Mol Med (Berl); 2021 Sep; 99(9):1293-1309. PubMed ID: 34047812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression and prognostic value of transporter 1, ATP binding cassette subfamily B member in clear cell renal cell cancer with experimental validation.
    Wang ZD; Tian X; Wang Y; Wang JJ; Ye SQ; Huang YQ; Qu YY; Chang K; Shi GH; Ye DW; Gu CY
    Front Oncol; 2022; 12():1013790. PubMed ID: 36419887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pan-cancer characterization of immune-related NFIL3 identifies potential predictive biomarker.
    Fei Q; Zhang X; Wang S; Shu G; Yin G
    J Cancer; 2024; 15(5):1271-1286. PubMed ID: 38356719
    [No Abstract]   [Full Text] [Related]  

  • 9. Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer.
    Yu L; Ding Y; Wan T; Deng T; Huang H; Liu J
    Front Immunol; 2021; 12():768115. PubMed ID: 34966389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
    Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
    Front Oncol; 2022; 12():927988. PubMed ID: 35756681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTPN1 is a prognostic biomarker related to cancer immunity and drug sensitivity: from pan-cancer analysis to validation in breast cancer.
    Zhao R; Chen S; Cui W; Xie C; Zhang A; Yang L; Dong H
    Front Immunol; 2023; 14():1232047. PubMed ID: 37936713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
    Huang S; Dong C; Li D; Xu Y; Wu J
    Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
    [No Abstract]   [Full Text] [Related]  

  • 13. Pan-cancer analysis of the prognostic and immunological role of Fanconi anemia complementation group E.
    Zhou Z; Yin H; Suye S; He J; Fu C
    Front Genet; 2022; 13():1024989. PubMed ID: 36685883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic analysis of
    Jiang Y; Wang X; Li L; He J; Jin Q; Long D; Liu C; Zhou W; Liu K
    Front Genet; 2022; 13():926943. PubMed ID: 35991552
    [No Abstract]   [Full Text] [Related]  

  • 16. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the immunological role and prognostic potential of PPM1M in pan-cancer.
    Zeng R; Wang L; Zhang Y; Yang Y; Yang J; Qin Y
    Medicine (Baltimore); 2023 Mar; 102(12):e32758. PubMed ID: 36961170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel LncRNA ZFHX4-AS1 as a Potential Prognostic Biomarker That Affects the Immune Microenvironment in Ovarian Cancer.
    Wang X; Wang Y; Sun F; Xu Y; Zhang Z; Yang C; Zhang L; Lou G
    Front Oncol; 2022; 12():945518. PubMed ID: 35903691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma.
    Shang BB; Chen J; Wang ZG; Liu H
    PeerJ; 2021; 9():e12315. PubMed ID: 34754620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
    Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
    Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.